Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
146 hedge funds and large institutions have $1.59B invested in Akero Therapeutics in 2022 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 53 increasing their positions, 27 reducing their positions, and 16 closing their positions.
382% more capital invested
Capital invested by funds: $330M → $1.59B (+$1.26B)
206% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 16
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
96% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 27
29% more funds holding
Funds holding: 113 → 146 (+33)
4.21% less ownership
Funds ownership: 104.87% → 100.67% (-4.2%)
44% less call options, than puts
Call options by funds: $23.7M | Put options by funds: $42.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$47.8M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$34.4M |
| 3 |
Janus Henderson Group
London,
|
+$18.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$15.4M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$24.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.7M |
| 3 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$18.9M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$10.4M |
| 5 |
Millennium Management
New York
|
-$4.92M |
AKRO Hedge Fund Activity: Q3 2022 in Review
146 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2022, worth a combined $1.59B — up 382% from $330M a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new AKRO positions and 16 closed out — a net gain of 33 holders — while 53 added to existing stakes and 27 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $47.8M. The largest seller was venBio Partners, cutting an estimated $24.1M.
- 146 institutional investors held Akero Therapeutics (AKRO) as of Q3 2022, up from 113 in Q2 2022.
- Funds reported $1.59B of Akero Therapeutics stock for Q3 2022, up 382% quarter-over-quarter.
- 49 funds opened new Akero Therapeutics positions in Q3 2022 and 16 closed out, a net change of +33 holders.
- The largest Akero Therapeutics buyer in Q3 2022 was Avidity Partners Management, an estimated $47.8M added.
- The largest Akero Therapeutics seller in Q3 2022 was venBio Partners, an estimated $24.1M sold.
Based on aggregated 13F filings for Q3 2022.